22 June 2018 - Adults with moderate to severe atopic dermatitis are a step closer to being able to routinely access treatment with Sanofi’s Dupixent on the NHS, following a green light from cost regulators.

The National Institute for Health and Care Excellence has published final draft guidance backing the drug’s use when the disease has not responded to at least one other systemic therapy, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are contraindicated or not tolerated.

Also, Sanofi must continue to provide Dupixent (dupilumab) as per the patient access scheme agreed with NHS England, and treatment should be stopped at 16 weeks if there has been no response.

Read Pharma Times article